Biotech stocks toppled Thursday after President Donald Trump announced broad global tariffs.A fact sheet from the White House ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

Should Regeneron wish to compete, they will have to lower their prices, thereby eating into their profit margins. Interestingly, at the recent Leerink Global Healthcare Conference, the CFO Chris ...

The Cambridge, Massachusetts-based biotech had divested its cell therapy R&D programs to Regeneron for $5 million upfront in early 2024. As the Leerink team noted, the company’s remaining ...

In a report released on March 2, David Risinger from Leerink Partners maintained a ... AnaptysBio, and Regeneron. According to TipRanks, Risinger has an average return of 10.3% and a 56.15% ...

Leerink analyst Roanna Ruiz downgraded Lexicon (LXRX) to Market Perform from Outperform with a price target of $1, down from $2. The “modest” efficacy, unclear dose response, and safety ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (LSE:0A4D) from Outperform to Market Perform. There are 35 funds or institutions reporting positions ...

Capricor management will present updates on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as provide other general scientific and corporate updates.

Audio webcasts and replays of available presentations will be accessible on MindMed’s Investor Relations website for up to 90 days following each event. MindMed is a late-stage clinical ...